-
Malaysia declares haze emergency in Sarawak state on Borneo
-
Stocks mixed before US jobs data, oil dips
-
East German refinery adjusts to life without Russian oil
-
Optimised urinals and buried underwear at 2026 Ig Nobels
-
Song Yadong looks to become China's first UFC champion after home victory
-
German factory orders rise again in latest recovery sign
-
India's Mandhana becomes top run-scorer in women's cricket
-
Nepal's 'Himalayan tsunami': what we know
-
IUX Announces Two New Podcast Series: IUX Market Trendline and The Market Journey
-
SPAYZ.io brings Africa’s payment growth story to Forex Expo Dubai 2026
-
Brussels Diamond League finals Day 2 - four events to watch
-
Zelensky slams his security services for 'unacceptable' shootout
-
Looming far-right win in Germany sparks security worries
-
Farage's Reform UK meets as new donation scandal hits
-
Tanker captain arrested over cargo ship sinking off Istanbul
-
Volunteers fight uphill battle against Indonesian fires
-
India hopes 'unique idea' will save athletes from cabin fever
-
PU Prime Launches Australian Operations under ASIC Licence
-
UK asserts 'unshakeable' Falklands commitment after Milei presses claim
-
Night-owl Zverev goes distance to advance as upsets rock US Open
-
How a Dostoevsky novella took TikTok by storm
-
Marathon man Zverev goes distance again to reach US Open third round
-
Zverev goes the distance again to reach US Open third round
-
US study tests psilocybin to fight cancer side effects
-
German AfD's love for Simson mopeds dismays Jewish family behind brand
-
Italy's Meloni throws party to celebrate record in power
-
Two trapped tunnel workers rescued in Nepal 'miracle'
-
After heatwaves, will EU pivot back to the climate fight?
-
Ex-Pakistan coach Gillespie tells Javed 'look in the mirror' over sackings
-
South Korean football referee faces hearing over 'period' insult
-
Monfils falls to Tien in US Open in Grand Slam farewell
-
Toulouse eye Top 14 history after 'difficult' summer
-
Arsenal brace for Chelsea test as Spurs seek spark
-
Springboks and All Blacks seek series lead after war of words
-
Efficient Rybakina reaches US Open third round
-
Bundesliga brings the band back together in Premier League's shadow
-
Taiwan boxer Lin considered 'graceful exit' after Paris Games gold
-
Asian stocks rally as traders pare rate bets ahead of jobs data
-
'I miss my home': Cambodians displaced by conflict start over
-
War-bruised Myanmar finds relief in bareknuckle bloodsport
-
Ailing Auger-Aliassime falls at US Open as Swiatek, Osaka and Gauff advance
-
Gauff downs Badosa to reach US Open third round
-
Tesla launches self-driving 'Cybercab' in Texas
-
New Zealand approves use of party drug MDMA to treat trauma
-
'Wallace & Gromit' creators turn 50 with spook-tacular Shaun yarn
-
Westerners test their mettle at World Nomad Games in Kyrgyzstan
-
New York's Muslims reclaim their city after 9/11 backlash
-
Gauff cruises into US Open third round
-
Premier League transfer windfall a lifeline for ailing French clubs
-
Kyrgios gets month ban for cocaine, enters treatment programme
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).
About PromiCell, Inc.
PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.
Contact:
305-433-1287
[email protected]
SOURCE: Promicell
View the original press release on ACCESS Newswire
M.A.Colin--AMWN